Results 61 to 70 of about 2,887 (179)

PREPARATION AND CHARATEIZATION OF OLMESARTAN MEDOXOMIL SOLID DISPERSION FOR THE DEVELOPMENT OF ORODISPERSABLE TABLETS

, 2016
Solid dispersions were prepared by solvent evaporation method with different carriers such as PVP-K90, mannitol and urea in different proportions. All the solid dispersions prepared were evaluated for saturation solubility study, drug content and for ...
O. Kumar*, A. Prameela Rani and V. Saikishore
core   +1 more source

Uptake and metabolization of four sartan drugs by eight different plants: Targeted and untargeted analyses by HPLC‐drift‐tube‐ion‐mobility quadrupole time‐of‐flight mass spectrometry

ELECTROPHORESIS, Volume 46, Issue 3-4, Page 135-142, February 2025.
Abstract In this study, we investigated the uptake and metabolization of four drugs (plus the associated prodrugs) from the sartan family by eight edible plants. Growing the plants hydroponically in a medium containing the respective drug, more than 40 phases I and II metabolites derived from the four sartan drugs could be tentatively identified.
Laura Zellner, Thomas Schiefer, Markus Himmelsbach, Franz Mlynek, Christian W. Klampfl   +4 more
wiley   +1 more source

ARB I olmesartan interruption in cardiovascular and cardiorenal continuum: antihypertensive and nephroprotective effects (part 1)

КардиоСоматика, 2014
The article provides an overview of the efficacy and tolerability of one of the representatives of the class angiotensin receptor blockers II - olmesartan medoxomil (Kardosal).
M. G Bubnova
doaj  

Association between chronic diseases and severe periodontal disease progression: A retrospective cohort study in a city of Japan

Journal of General and Family Medicine, Volume 26, Issue 1, Page 54-64, January 2025.
This manuscript is a study demonstrating the association between the progression of severe periodontal diseases and chronic diseases commonly addressed in primary care. We used claims data and defined the outcome as the “progression of severe periodontitis” and followed patients for 4 years.
Sayaka Nin, Yu Sun, Takami Maeno, Chihiro Nishiura, Kento Taira, Kenji Fujimoto, Jun Hamano, Sachiko Ozone, Tetsuhiro Maeno   +8 more
wiley   +1 more source

Simultaneous Analytical Method Development and Validation of Rosuvastatin and Olmesartan Medoxomil in Combined Tablet Dosage form by RP-HPLC

, 2021
A RP-HPLC method for Rosuvastatin and Olmesartan medoxomil was developed and Validated in tablet dosage form as pre ICH Guide lines UV visible Detector and Column C18(150 × 4.6mm)5μ injection of 20μl is injected and eluted with the mobile phase of ...
Babu, R
core  

Efficacy of Olmesartan/Amlodipine Single‐Pill Combination on 24‐h Mean Systolic Blood Pressure Measured by Ambulatory Monitoring in Non‐Responders to Valsartan or Candesartan Monotherapy

The Journal of Clinical Hypertension, Volume 27, Issue 1, January 2025.
ABSTRACT The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single‐pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in non‐responders to valsartan or candesartan monotherapy. Isolated systolic hypertension (ISH) is the most prevalent form of hypertension in middle‐aged and elderly ...
Woo‐Baek Chung, Sang‐Hyun Ihm, Yun‐Seok Choi, Ho‐Joong Youn   +3 more
wiley   +1 more source

Method Development and Validation of simultaneous estimation for Amlodipine besylate and Olmesartan medoxomil by HPTLC method

, 2018
The present work deals with method development and analytical validation of a novel, precise and accurate HPTLC methods for the simultaneous estimation of Amlodipine besylate and Olmesartan medoxomil.
Manikandan K, Peddamadi Bhavya Sree, Sonia K, Hamunyare Ndwabe, Lakshmi KS   +4 more
core   +1 more source

Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT)

The Journal of Clinical Hypertension, Volume 27, Issue 1, January 2025.
ABSTRACT Angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) are commonly prescribed as first‐ and second‐line treatments for older Japanese patients with hypertension. However, due to age‐related decline in renin activity, the effectiveness of ARBs may decrease.
Kazuomi Kario, Tomohiro Katsuya, Tatsuo Shimosawa, Takashi Taguchi, Ayumi Tanabe, Mitsuru Ohishi, the ESCORT‐HT investigators   +6 more
wiley   +1 more source

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL

Российский кардиологический журнал, 2010
Endothelial dysfunction is the common link between cardiovascular disease risk factors and the earliest event in the cascade of incidents that results in target organ damage.
C. Ferrario
doaj  

Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers

Current Therapeutic Research, 2014
Background: Olmesartan is an angiotensin II receptor antagonist and is effective and well tolerated in the treatment of arterial hypertension. Probenecid is a well-established hypouricemic agent for the treatment of hyperuricemia and gout. Objective: The
Kun-Yan Li, PhD, Yu Qiu, MS, Yun Jiang, BS, Chen-Hui Luo, MS, Xiao-Ping Lin, BS, Jing Wang, BS, Nong Yang, MS   +6 more
doaj   +1 more source